Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction

• Published in: Diabetes care Vol. 23; no. 2; pp. 163 - 170
• Main Authors: Cox, D J, Gonder-Frederick, L A, Kovatchev, B P, Julian, D M, Clarke, W L
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.02.2000
• Subjects: Adult; Associated diseases and complications; Automobile Driving; Awareness; Biological and medical sciences; Blood Glucose - metabolism; Diabetes Mellitus, Type 1 - drug therapy; Diabetes. Impaired glucose tolerance; Electroencephalography; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Female; Glycated Hemoglobin A - analysis; Humans; Hypoglycemia - chemically induced; Hypoglycemia - physiopathology; Hypoglycemia - psychology; Male; Medical sciences; Endocrinopathy; Performance evaluation; Human; Immunopathology; Attentional disorder; Simulation; Vehicle driving; Attention; Insulin dependent diabetes; Autoimmune disease; Hypoglycemia
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/diacare.23.2.163

Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. D J Cox , L A Gonder-Frederick , B P Kovatchev , D M Julian and W L Clarke Behavioral Medicine Center, University of Virginia Health System, Charlottesville 22908, USA. djc4f@virginia.edu Abstract OBJECTIVE: Progressive hypoglycemia leads to cognitive-motor and driving impairments. This study evaluated the blood glucose (BG) levels at which driving was impaired, impairment was detected, and corrective action was taken by subjects, along with the mechanisms underlying these three issues. RESEARCH DESIGN AND METHODS: There were 37 adults with type 1 diabetes who drove a simulator during continuous euglycemia and progressive hypoglycemia. During testing, driving performance, EEG, and corrective behaviors (drinking a soda or discontinuing driving) were continually monitored, and BG, symptom perception, and judgement concerning impairment were assessed every 5 min. Mean +/- SD euglycemia performance was used to quantify z scores for performance in three hypoglycemic ranges (4.0-3.4, 3.3-2.8, and <2.8 mmol/l). RESULTS: During all three hypoglycemic BG ranges, driving was significantly impaired, and subjects were aware of their impaired driving. However, corrective actions did not occur until BG was <2.8 mmol/l. Driving impairment was related to increased neurogenic symptoms and increased theta-wave activity. Awareness of impaired driving was associated with neuroglycopenic symptoms. increased beta-wave activity, and awareness of hypoglycemia. High beta and low theta activity and awareness of both hypoglycemia and the need to treat low BG influenced corrective behavior. CONCLUSIONS: Driving performance is significantly disrupted at relatively mild hypoglycemia, yet subjects demonstrated a hesitation to take corrective action. The longer treatment is delayed, the greater the neuroglycopenia (increased theta), which precludes corrective behaviors. Patients should treat themselves while driving as soon as low BG and/or impaired driving is suspected and should not begin driving when their BG is in the 5.0-4.0 mmol/l range without prophylactic treatment.